Clinical Trial Update: Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety and efficacy of single weekly bortezomib in newly diagnosed multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Boston VA Research Institute, Inc. | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2020-08-20